Katrina Abuabara, MD
Dermatology · Philadelphia, PANPI 1558689216
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Sanofi at 41.4% of the total. Reporting peaked in 2024 at $27,070 and has fallen 71.9% since, to $7,618 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 23 payments — averaging $1510.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$14K
- Amgen$11K
- Incyte Corporation$9K
- AbbVie$31
- LEO Pharma Inc.$25
Across 10 payments — averaging $32,608 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$324K
- Regeneron$2K
What the payments were for
- Consulting fees$17,69051%
- Speaking & faculty fees$13,19838%
- Travel & lodging$3,60710%
- Food & beverage$2241%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $14,380 |
| Amgen | 7 | $11,130 |
| Incyte Corporation | 7 | $9,178 |
| AbbVie | 1 | $31 |
| LEO Pharma Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPZELURA$9,136
How this compares
$34,744 in reported general payments places this provider in the 90th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 14 | $47,601 |
| Clobetasol Propionate | 16 | $1,776 |
| Ketoconazole | 15 | $423 |
| Triamcinolone Acetonide | 15 | $171 |
| Alendronate Sodium | 12 | $35 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $13 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Philadelphia
- Stephen HessPhiladelphia$1.7M
- Joel GelfandPhiladelphia$649K
- Victoria WerthPhiladelphia$547K
- Nicholas MollanazarPhiladelphia$369K
- Harold FarberPhiladelphia$284K
- Jules LipoffPhiladelphia$259K
- Susan TaylorPhiladelphia$207K
- Joy WanPhiladelphia$176K
- Harold MilsteinPhiladelphia$120K
- David MargolisPhiladelphia$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.